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What is already known about this topic? 
 Factors that might influence response to systemic treatment for moderate-to-severe psoriasis 
are generally poorly understood, aside from high body weight, suggesting that other 
unidentified factors may be relevant in determining response to treatment.  
 The potential influence of alcohol abuse on response to treatment for psoriasis has not been 
previously investigated.
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 After adjusting for important factors that could influence response to treatment such as 
psychological distress and medication non-adherence, alcohol abuse was found to be 
significantly associated with poor response to treatment.
 Identification of potentially modifiable factors associated with poor treatment response 
emphasises the need for lifestyle behaviour change support as part of routine clinical care. 
 Effective interventions to detect and address high alcohol consumption should form part of 
routine care for people with psoriasis.
Abstract 
Background: Factors that might influence response to systemic treatment for moderate-to-severe 
psoriasis are varied, and generally, are poorly understood, aside from high body weight, 
suggesting that other unidentified factors may be relevant in determining response to treatment. 
The impact of alcohol abuse on treatment response has not been previously investigated.
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Methods: Prospective cohort study in which response to systemic therapies was assessed using the 
Psoriasis Area and Severity Index (PASI). The CAGE questionnaire was used to screen for alcohol 
abuse. A multivariable factional polynomial linear regression model was used to examine factors 
associated with change in PASI between baseline and follow-up.
Results: The cohort comprised of 266 patients (biologic cohort, n=134; conventional systemic 
cohort, n=132). For the entire cohort, the median (interquartile range) PASI improved from 13[10-
18.3] at baseline to 3[1-7.5] during follow-up. A higher CAGE score (regression co-efficient: 
1.40; 95% CIs: 0.04-2.77); obesity (1.84; 0.48-3.20); and receiving a conventional systemic rather 
than a biologic therapy (4.39; 2.84-5.95) were significantly associated with poor response to 
treatment; whereas a higher baseline PASI (-0.83; -0.92,-0.74) was associated with better response 
to treatment.
Conclusion: The poor response to therapy associated with alcohol abuse and obesity found in 
people with psoriasis calls for lifestyle behaviour change interventions and support as part of 
routine clinical care. Targeting interventions to prevent, detect and manage alcohol abuse among 
people with psoriasis is needed to minimise adverse health consequences and improve treatment 
response. 
Introduction
Psoriasis is a chronic, immune-mediated inflammatory skin condition; recognised by the World 
Health Organization as a serious non-communicable disease that requires effective management.1 
The psychological and social difficulties in combination with the physical discomfort associated 
with psoriasis may contribute to psychological distress (anxiety and depression) and alcohol 
abuse.2-4 
Treatment effectiveness of conventional systemic and biologic therapies used in the management 
of moderate-to-severe psoriasis is much lower in real-world clinical practice than in clinical 
trials.5,6 Factors that might influence response to treatment are varied, and generally, are poorly 
understood, aside from high body weight, which has consistently been associated with worse 
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determining response.13 To date, previous research has focused on demographic, and clinical 
factors as predictors of response to treatment in psoriasis.12 However, there are no studies 
examining the role of alcohol abuse in predicting response to treatment, taking into account other 
important factors that could also influence treatment response such as psychological distress and 
medication non-adherence.
The iMAP (Investigating Medication Adherence in Psoriasis) is a multi-centre study collecting 
biomedical and psychological data from patients with psoriasis prescribed biologic or 
conventional systemic therapies.14 All patients in iMAP are also enrolled in the British Association 
of Dermatologists Biologics and Immunomodulators Register (BADBIR), a longitudinal 
pharmacovigilance register representing a "real-world" cohort of patients with psoriasis receiving 
biologic or conventional systemic therapies.15,16 This presents an ideal resource to assess the 
impact of alcohol abuse, alongside patient behavioural and psychological factors on response to 
conventional systemic and biologic therapies in routine clinical practice. The objectives of this 
study were to: (i) assess real-world levels of alcohol abuse, psychological distress and medication 
non-adherence among patients with moderate-to-severe psoriasis and; (ii) investigate whether 




Patients attending 35 dermatology centers across England were recruited into iMAP between 
March 2013 and September 2016. Patients aged ≥18 years with a diagnosis of psoriasis under the 
care of a dermatologist, prescribed a conventional systemic and/or a biologic treatment and 
enrolled in BADBIR were eligible for inclusion into iMAP.14
Data collection
The CAGE (Cut down, Annoyed, Guilty, Eye opener) questionnaire assessed self-perception of 
alcohol abuse. It consists of 4 questions beginning with the stem "Have you ever": felt the need 
to cut down drinking; felt annoyed by criticism of drinking; had guilty feeling about drinking; and 
taken a morning eye opener. The items are rated on a scale of 0-1, with a total score ranging from 
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The Medication Adherence Report Scale (MARS) assessed the frequency of non-adherent 
behaviours on a 5-point Likert scale ranging from very often (1-point) to never (5-points), with 
scores ranging from 8 to 40, with higher scores indicating higher levels of adherent behaviour.19 
Patients were classified into overall non-adherent category if they scored ≤38/40.14 
The Hospital Anxiety and Depression Scale (HADS) is a 14-items scale which provided an 
assessment of symptoms of anxiety (7-items) and depression (7-items). Items are rated on a scale 
of 0-3, indicating the strength of agreement with that item and are summed to create a HADS 
anxiety and depression score, both ranging from 0 to 21, with a score of  ≥8 indicating a possible 
caseness of anxiety or depression.20,21 A score ranging between 8-10, 11-14 and 15-21 indicate 
mild, moderate and severe symptoms, respectively.22
Patients were instructed to independently and anonymously complete an iMAP questionnaire that 
contained the MARS and the HADS at baseline (upon recruitment) and every 6 months thereafter 
for up to 18 months. Patients' demographic characteristics (age, sex, height and weight); lifestyle 
information (smoking status and alcohol abuse [CAGE]); details of type and severity of psoriasis 
(Psoriasis Area and Severity Index [PASI]) and year of onset; standardised measures of health 
status using self-reported outcome measures (Dermatology Life Quality Index [DLQI]); detailed 
information about the patients' current and previous treatments for psoriasis (any change in 
therapy, concomitant use of systemic therapies, gaps in treatment, start and stop dates, and reasons 
for discontinuation); and the patients' comorbidities were extracted from BADBIR (with written 
informed patient consent) at times corresponding to the dates when the patients completed the 
iMAP questionnaires. Data were extracted from the October 2018 database build. 
Study population
Patients were eligible for inclusion in this analysis if they had at least one PASI measurement 
recorded before and after completing at least one iMAP questionnaire. The PASI recorded closest 
to the date of completing the iMAP questionnaire were identified and referred to as either 
“baseline” (recorded prior to completing the questionnaire) or “follow-up” PASI (recorded after 
completing the questionnaire). Majority of the patients had only one iMAP questionnaire, while 
few had multiple questionnaires completed between the time the baseline and follow-up PASIs 
were recorded (Figure S1). Patients were excluded from the analysis if the baseline PASI was 
measured >12 months prior to or >1 month after the start of therapy; and/or if their follow-up 
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assigned to either the biologic or conventional systemic cohort based on the therapy they were 
receiving at the time of completing their first iMAP questionnaire, and recorded as either biologic 
naïve or non-naïve. 
Statistical analysis
Multivariable linear regression model, where fractional polynomials were used to model non-
linear relationships between the covariates and the outcome, was conducted to investigate factors 
associated with the change in PASI between baseline and follow-up. An a priori list of covariates 
was determined to address potential predictors of response. Alcohol abuse (CAGE), medication 
non-adherence and psychological distress recorded at times corresponding to the dates when the 
patients completed the iMAP questionnaires were included in the model. In the few patients with 
more than one valid measurements of the CAGE (19 patients [7%]), patients' medication non-
adherence status (28 patients [11%]) and psychological distress (28 patients [11%]) during the 
study period, an average was taken. An interaction between overall medication non-adherence 
status and the cohort the patients was assigned to was also included in the model. 
Other potential confounders included in the model was body mass index (dated around the start 
date of the therapy) which was categorised into a binary obese/non-obese variable. The patients' 
age and disease duration were calculated from the patients' date of birth and year of disease onset 
recorded at the time of registration into BADBIR and the start date of their therapy, respectively. 
Baseline DLQI were identified if they were dated within 12 months prior to and 1 month after the 
start of treatment to be consistent with how baseline PASI were identified (the median 
[interquartile range] time period between the baseline DLQI measurement and start of therapy was 
-4 days [-37 days – 0 days]). Comorbidities with inflammatory arthritis and other comorbidities as 
well as the patients' smoking status were collected at the time of registration into BADBIR. 
Concomitant use of methotrexate, ciclosporin and/or other conventional systemic therapies was 
analysed as a binary variable (ever exposed/never exposed) throughout the study. A sensitivity 
analysis was conducted in which an interaction between alcohol abuse and obesity was also 
included in the model.
To account for missing data (Table S1), we generated 50 imputed datasets. In each dataset, 
missing values were replaced by values randomly selected from the expected distribution of that 
variable conditional on the measured or imputed values of all other variables for that individual. 
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be likely if only subjects with complete data were analyzed.23 The multivariable linear regression 
assumptions were assessed by scatterplots and statistical testing. Analyses were performed using 
STATA version 15.0 (Stata Corp, College Station, TX).
Ethical approval
Ethical approvals for BADBIR and iMAP were obtained from the NHS research Ethics 
Committee North West England (references 07/MRE08/9 and 12/NW/0619, respectively) in 
March 2007 and December 2012, respectively, and from research ethics committees local to each 
recruiting site. All subjects gave written informed patient consent for their participation in the 
registry prior to data collection. 
Results
In total, 266 patients with psoriasis (biologic cohort, n=134; conventional systemic cohort, n=132) 
followed-up for a median (interquartile range) of 7[6-10] months were included in our analyses 
(Figure 1). The mean ± standard deviation age of patients and disease duration were 48.2±13.1 and 
22.1±14.5 years, respectively, with 45.1% female. At baseline, the median (interquartile range) 
PASI was 13[10-18.3] and the mean DLQI was 16.2±8.5. Overall, 19.6% reported having 
inflammatory arthritis, and 67.3% reported having ≥1 comorbidities other than inflammatory 
arthritis. Patients' demographic and disease characteristics are summarised in Table 1. 
The mean CAGE score was 0.3±0.8, with 5.8% of patients scoring ≥2 indicating alcohol abuse 
(Table 1). The mean HADS anxiety and depression scores were 6.9±4.5 and 5.3±4.1, with 40.5% 
and 27.6% of patients scoring ≥8 indicating a possible caseness of anxiety and depression, 
respectively (Table 1). A notable proportion of the study cohort were classified as non-adherent 
(16.6%; Table 1), with a significantly higher proportion of patients using conventional systemic 
therapies classified as non-adherent (27.6%) compared to those using biologic therapies (5.9%). 
Table 2 presents results from the multivariable linear regression analysis examining factors that 
affect the change in PASI between baseline and follow-up. Having a higher CAGE score was 
significantly associated with poor response to treatment as measured by change in PASI (for every 
1 point increase in the CAGE score; regression coefficient 1.40; 95% CIs: 0.04, 2.77. Thus a 
maximum change in CAGE score from 0 to 4 would be associated with a change in PASI of 5.60; 
0.16, 11.08). Of the demographic factors, with each 10-year increase in a patient's age there was 
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every 1 point increase in the baseline PASI; -0.83; -0.92, -0.74) was also significantly associated 
with a better response to treatment, whereas being obese (1.84; 0.48, 3.20); receiving a 
conventional systemic therapy rather than a biologic therapy (4.39; 2.84, 5.95), and stopping the 
therapy during the follow-up (4.18; 2.38, 5.97) were significantly associated with poor response to 
treatment. No significant interaction was found between medication non-adherence and treatment 
cohort (P=0.336, Table 2) and also between alcohol abuse (CAGE) and obesity (P=0.930, Table 
S2).      
Discussion
Main findings
In this real-world cohort of patients with psoriasis, alcohol abuse, obesity, and receiving a 
conventional systemic therapy were significantly associated with poor response to treatment as 
measured by change in PASI between baseline and follow-up. To our knowledge this is the first 
study to investigate alcohol abuse in a real-world cohort of patients with psoriasis, and explore 
how it affects response to treatment. 
Comparison to other studies
Consistent with other studies, we found that obesity was also associated with poor response to 
systemic therapies.7-9 Obesity has also been found to be associated with poor response to therapies 
in rheumatoid arthritis24,25 and ankylosing spondylitis.26 Our findings are also in-line with those 
reported by Gelfand et al.5, who found biologic therapies to be more effective than conventional 
systemic therapies. However, by comparison, our study has an important strength: we accounted 
for important clinical and social factors including smoking status, alcohol abuse, the presence of 
comorbidities, and medication non-adherence. Although overall non-adherence did not 
significantly predict response to therapy (P=0.522), the results suggest that it was associated with 
poor response for those exposed to conventional systemic therapies (2.65; -5.49, 10.79). Clinicians 
should therefore explore patients' adherence, especially in those who are poor responders to 
therapy, and provide additional support to improve adherence to treatment regimens.27 Future 
studies investigating predictors of response to therapy should ideally include a measure of 
adherence to reduce potential confounding.
To our knowledge, no previous study has assessed the association of alcohol abuse with poor 
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to treatment. We would be interested to see whether our findings can be replicated independently. 
The implications of our findings are important. The economic, social and health consequences of 
alcohol abuse are considerable. Excessive alcohol may worsen the disease, has implications for 
treatment, and increases the risk of dying in people with psoriasis, on average 3 years younger, 
compared with peers of the same age and sex in the general population.28,29
Strengths and limitations
One of the key strengths of this study is the real-world prospective cohort study design thus 
ensuring that patients are representative of those receiving treatment in routine clinical practice. 
Furthermore, the participation of multiple dermatology centers (n=35) across England ensures the 
external validity of the results. We also performed multiple imputation to account for missing data 
thus minimising the bias that could have been introduced by only considering a complete case 
analysis. Self-reported tools of alcohol abuse, medication non-adherence and psychological 
distress can be criticised for being influenced by poor patient recall or reporting bias and so can 
underestimate alcohol abuse or overestimate adherence and psychological distress. The CAGE 
questionnaire can also be criticised for identifying mostly the severe forms of harmful alcohol 
abuse and dependence, and so can fail to adequately identify those with hazardous use of alcohol. 
Nevertheless, it is reported that the CAGE has a sensitivity of 93% and a specificity of 76% for the 
identification of excessive drinking and the use of appropriate theoretical frameworks and 
validated data collection tools are major strengths.30,31 An inherent limitation in any observational 
study is lack of randomisation, which may introduce confounding bias, and although this is 
partially negated by adjustment for clinically relevant covariates, the presence of other 
unmeasured confounders, such as the intention behind concomitant medication, cannot be 
determined. One particular challenge we faced is that some of the patients’ demographic 
characteristics were recorded only at the time of registration with BADBIR. This included data on 
smoking status and comorbidities. It is possible that some patients may have developed new 
comorbidities or changed smoking status during the study period. Furthermore, the influence of 
treatment dose escalation on the PASI response was not assessed. However, we have shown 
previously that patients in BADBIR routinely receive the recommended dosing regimen but that 
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Clinicians should be aware of the considerable psychological distress and psychosocial challenges 
that are faced by patients with psoriasis which can lead to chronic alcohol abuse and dependence 
as coping mechanisms.29 Our findings highlight that at least 40% of our study cohort reported 
having psychological distress and that alcohol abuse has a negative effect on response to 
treatment. Psychological and educational interventions for newly diagnosed patients with psoriasis  
have been  developed to minimise distress and to alert patients to the negative impact of alcohol 
on psoriasis outcomes [e.g. Chisholm et al.33 and Nelson et al.34]. For those with established 
disease, the recognition by clinicians of the risks associated with the dual stigma of psoriasis and 
alcohol abuse on response to treatment is important. Discussions about alcohol use, especially 
high use, are challenging for both clinicians and patients through fear of stigmatisation, and as a 
result, are frequently avoided in consultations.35 Patients may also be unaware of the extent to 
which they are using alcohol as a coping mechanism. Nevertheless, provision of skilled screening 
and brief interventions by healthcare teams can enable patients to achieve reduction or abstinence, 
reduce health harms and improve prognosis without increasing stigma.36-38
Our findings also indicate that clinicians need to be aware of, and address, the possibility of 
medication non-adherence. More than 15% of patients in this study were classified as non-
adherent. Patients’ beliefs about their medication, including concerns about the potential for 
adverse events, are key drivers of non-adherence. Concerns about unwanted treatment effects are 
common in patients with psoriasis, including those who adhere to treatments,39 and so provision of 
accessible patient-centred materials (using traditional written or e-health delivery formats) which 
address these issues may allay some worry in a time efficient way. This can be further supported 
by all those involved in provision of treatment, medical, nursing and pharmacy staff, all of whom 
have a role in shaping patients’ treatment beliefs. People are more likely to forget to use their 
medication if they have weak medication-taking habits or routines.14 Again, very brief messages 
either delivered directly from relevant clinical staff, or via traditional or electronic media, may 
enable patients to recognise that habit formation requires an initial period of active engagement in 
change and could optimise treatment outcomes.27
Conclusions
This study provides evidence that alcohol abuse and obesity are associated with poor response to 
treatment in patients receiving systemic therapies. These are modifiable factors and confirm the 
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psoriasis. Interventions to prevent or address alcohol abuse and weight gain are important parts of 
psoriasis health management. Patients may need additional support to recognise the relevance of 
these lifestyle factors to their skin health;34,40 and this study highlights how these factors 
detrimentally affect psoriasis treatment effectiveness. Routine screening, and identification, using 
simple screening tools, can be used to detect early signs of hazardous, harmful and dependent 
alcohol consumption which could be implemented in healthcare settings to detect alcohol abuse 
among people with psoriasis.38
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Figure 1: Flow chart showing selection of study participants.
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Table 1: Patients' demographic and disease characteristics.
Table 2: Multivariable linear regression of potential factors associated with changes in PASI 
























Table 1: Patient demographic and disease characteristics 
 All patients 
(n = 266) 
Biologic cohort1 
(50.4%, n = 134) 
Conventional cohort2 
(49.6%, n = 132) 
Age (years), mean ± SD 48.2 ± 13.1 48.1 ± 13.5 48.4 ± 12.8 
Female 120 (45.1%) 52 (38.8%) 68 (51.5%) 
BMI category, Kg/m2 
Non-obese (BMI < 30) 145 (54.4%) 63 (46.9%) 82 (62.1%) 
Obese (BMI ≥ 30) 121 (45.7%) 71 (53.1%) 50 (38.1%) 
Smoking status 
Never smoked 86 (32.5%) 47 (35.0%) 40 (30.0%) 
Ex-smoker 98 (36.9%) 52 (39.1%) 46 (34.6%) 
Current smoker 82 (30.6%) 35 (25.9%) 47 (35.4%) 
Alcohol Use 
CAGE3, mean ± SD 0.3 ± 0.8 0.3 ± 0.7 0.3 ± 0.8 
21 
 
Alcohol abuse  15 (5.8%) 7 (5.6%) 8 (6.1%) 
Inflammatory arthritis/ Other comorbidities 
Inflammatory arthritis 52 (19.6%) 30 (22.4%) 22 (16.7%) 
No comorbidities4 87 (32.7%) 39 (29.1%) 48 (36.4%) 
1-2 comorbidities4 122 (45.9%) 63 (47.0%) 59 (44.7%) 
3-4 comorbidities4 50 (18.8%) 28 (20.9%) 22 (16.7%) 
≥ 5 comorbidities4 7 (2.6%) 4 (3.0%) 3 (2.3%) 
Disease 
Disease duration (years), mean ± 
SD 
22.1 ± 14.5 23.6 ± 14.0 20.5 ± 14.9 
Age of onset (years), mean ± SD 26.2 ± 15.9 24.4 ± 15.2 27.9 ± 16.5 
PASI at baseline, median[IQR] 13.1 [10 - 18.3] 13.4 [9.2 - 19.4] 12.8 [10.2 - 17.1] 
DLQI at baseline, mean ± SD 16.2 ± 8.5 15.8 ± 9.4 16.5 ± 7.6 
Unstable psoriasis 37 (13.9%) 17 (12.7%) 20 (15.2%) 
Psychological distress (HADS) 
Anxiety score5, mean ± SD 6.9 ± 4.5 6.7 ± 4.3 7.0 ± 4.6 
Anxiety severity6 
No anxiety 158 (59.5%) 80 (59.7%) 78 (59.3%) 
Mild anxiety 53 (19.9%) 29 (21.3%) 24 (18.5%) 
Moderate anxiety 39 (14.5%) 19 (14.3%) 20 (14.6%) 
Severe anxiety 16 (6.1%) 6 (4.7%) 10 (7.6%) 
Depression Score5, mean ± SD 5.3 ± 4.1 5.3 ± 4.1 5.3 ± 4.2 
Depression severity6 
No depression 193 (72.4%) 99 (73.9%) 94 (70.9%) 
Mild depression 41 (15.3%) 20 (14.6%) 21 (16.1%) 
Moderate depression 27 (10.4%) 13 (10.0%) 14 (10.7%) 
Severe depression 5 (1.9%) 2 (1.5%) 3 (2.3%) 
Medication non-adherence 
Overall non-adherent, n (%) 44 (16.6%) 8 (5.9 %) 36 (27.6%) 
Medication history 
Biologic naïve 238 (89.5%) 106 (79.1%) 132 (100.0%) 
Concomitant systemic therapy7 28 (10.5%) 17 (12.7%) 11 (8.3%) 
Stopped Therapy8 42 (15.8%) 16 (11.9%) 26 (19.7%) 
22 
 
Abbreviations: CAGE, Cut down, Annoyed, Guilty and Eye Opener; DLQI, Dermatology Life Quality 
Index; HADS, Hospital Anxiety and Depression Scale; IQR, Interquartile range; PASI, Psoriasis Area 
and Severity Index; SD, Standard Deviation.  
1 Includes adalimumab (69, 51.5%); etanercept (17, 12.7%); ustekinumab (45, 33.6%); and other biologic 
therapies [infliximab, golimumab, secukinumab] (3, 2.3%) 
2 Includes acitretin (33, 25.0%); ciclosporin (32, 24.2%); Fumaric acid esters (7, 5.3%); methotrexate 
(60, 45.5%). 
3 The possible score range for CAGE is 0-4. 
4 Includes any of (excluding inflammatory arthritis) hypertension, angina, ischemic heart disease, stroke, 
epilepsy, asthma, chronic obstructive pulmonary disease, peptic ulcer, renal disease, hepatic disease, 
tuberculosis, demyelinating disease, diabetes, impaired glucose tolerance, depression, non-skin cancer, 
immunodeficiency syndrome, thyroid disease, other.  
5 The possible score range for HADS anxiety and HADS depression is 0-21. 
6 The possible score range for HADS anxiety and HADS depression severity is mild, 8-10; moderate, 11-
14; severe, 15-21. 
7 Includes any of acitretin, fumaric acid esters, ciclosporin, methotrexate and mycophenolate mofetil. 










Table 2: Multivariable linear regression of potential factors associated with changes in PASI 
between baseline and follow-up.  
Variable Β coefficient (95% CIs) P-value 
Demographics 
Agea -0.63 (-1.22,-0.05) 0.035 
Female -0.05 (-1.37, 1.27) 0.940 
Obesity statusb 
Obese (BMI 30 kg/m2 ) 1.84 (0.48, 3.20) 0.008 
Smoking statusc 
Ex-smoker -1.21 (-2.75, 0.33) 0.123 




Inflammatory arthritis -0.28 (-1.96, 1.40) 0.745 
1-2 comorbidities -0.40 (-1.88, 1.08) 0.595 
3-4 comorbidities 0.30 (-1.75, 2.35) 0.774 
≥ 5 comorbidities -1.31 (-5.62, 2.99) 0.549 
Disease 
Disease durationa 0.28 (-0.21, 0.77) 0.258 
Baseline PASI -0.83 (-0.92, -0.74) <0.0001 
Baseline DLQI -0.06 (-0.17, 0.06) 0.339 
CAGE 1.40 (0.04, 2.77) 0.044 
Psychological distress (HADS) 
Anxiety -0.03 (-0.24, 0.17) 0.74 
Depression 0.18(-0.04, 0.39) 0.110 
Overall non-adherent 2.65 (-5.49, 10.79) 0.522 
Treatment 
Conventional systemic cohorte 4.39 (2.84, 5.95) <0.0001 
Biologic naïvef -1.76 (-4.19, 0.68) 0.156 
Concomitantly using conventional systemic 
therapyg 
1.78 (-0.36, 3.91) 0.102 
Stopped therapyh 4.18 (2.38, 5.97) <0.0001 
Time gap between start of therapy and time the 
baseline PASI was measured 
0.21 (-0.22, 0.65) 0.334 
Time gap between start of therapy and time the 
follow-up PASI was measured 
-0.12 (-0.28, 0.04) 0.138 
Non-adherence: Conventional systemic cohorti -2.20 (-6.68, 2.29) 0.336 
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Abbreviation: BMI, body mass index; CAGE, Cut down, Annoyed, Guilty and Eye Opener; DLQI, 
Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale, PASI, Psoriasis Area 
Severity Index.  
Boldface indicates P ≤ 0.05. Fractional polynomials were used to determine if any non-linear association 
between the covariates and the outcome provided a better fit than a simple linear association, but none 
did.  
a To evaluate regression coefficients for every 10-year increase in age and disease duration at enrolment 
into the BADBIR, baseline continuous variables of age and disease duration were transformed to age and 
disease duration divided by 10. At follow-up, older age at enrolment (by 10 years) was associated with 
higher improvement in PASI values. 
b Reference category: non-obese (BMI<30 kg/m2). 
c Reference category: never smoked. 
d Reference category: no comorbidities (excluding inflammatory arthritis); includes any of hypertension, 
angina, ischemic heart disease, stroke, epilepsy, asthma, chronic obstructive pulmonary disease, peptic 
ulcer, renal disease, hepatic disease, tuberculosis, demyelinating disease, diabetes, impaired glucose 
tolerance, depression, non-skin cancer, immunodeficiency syndrome, thyroid disease, other. 
e Reference category: biologic cohort. 
f Reference category: biologic non-naïve. 
g Includes any of acitretin, fumaric acid esters, ciclosporin, methotrexate and mycophenolate mofetil. 
Included as a binary variable (ever exposed/never exposed). Reference category: never exposed.  
h Patients stopped therapy received at the time of completing the iMAP questionnaire during the study 
period. Reference category: continuously used therapy throughout the study period. 







































*The PASI recorded closest to the date of completing the iMAP questionnaire were 
identified and referred to as either baseline PASI (recorded prior to completing the 
questionnaire) or follow-up PASI (recorded after completing the questionnaire). 
Completed iMAP questionnaire 
(n = 811) 
Matched to BADBIR 
(n = 720) 
•  Missing BADBIR ID (n = 50) 
•  Patient invalid in BADBIR (n = 41) 
Included in the analysis 
(n = 266) 
•  Excluded because baseline PASI* was 
recorded >12 months before or >1 months 
after the start of treatment (n = 449) 
•  Excluded because follow-up PASI* was 
recorded >24 months after the start of 
treatment (n = 3) 
•  Excluded because patients were enrolled 
into the conventional systemic cohort but 
had previously failed biologic therapies (n 
= 2) 
Eligible participants 
(n = 1132) 
•  Declined post-consent (n = 16) 
•  Did not return the questionnaire (n = 305) 
Provided informed consent 
(n = 1146) 
Ineligible due to treatment type (n = 14) 
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